(Q44734491)

5 December 2017

title

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia (English)

1 reference

5 December 2017

0 references

1 reference

5

Daniel C Javitt

1 reference

5 December 2017

Uriel Heresco-Levy

1

1 reference

5 December 2017

Marina Ermilov

series ordinal

2

1 reference

5 December 2017

Pesah Lichtenberg

series ordinal

3

1 reference

5 December 2017

Gali Bar

series ordinal

4

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

5 December 2017

published in

Biological Psychiatry

1 reference

5 December 2017

volume

55

1 reference

5 December 2017

issue

2

1 reference

5 December 2017

page(s)

165-171

1 reference

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Placebo-controlled trial of glycine added to clozapine in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Recent advances in the phencyclidine model of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Amelioration of negative symptoms in schizophrenia by glycine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Glycine potentiates the NMDA response in cultured mouse brain neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Developmental changes in NMDA receptor glycine affinity and ifenprodil sensitivity reveal three distinct populations of NMDA receptors in individual rat cortical neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Cerebrospinal fluid amino acid concentrations in chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Five-factor model of schizophrenia. Initial validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

NR2B selective NMDA receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Glycine therapy in 7 cases of spasticity. A pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Antagonism of phencyclidine-induced hyperactivity by glycine in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

D-serine added to antipsychotics for the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Schizophrenia and glutamatergic transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900707-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(03)00707-8

1 reference

5 December 2017

1 reference